Galderma的新型类维生素A乳膏获得FDA批准,用于痤疮的局部治疗

2019-10-05 不详 MedSci原创

AKLIEF乳霜是唯一选择性靶向视黄酸受体(RAR)γ(皮肤中最常见的RAR)的局部类维生素A。Trifarotene是二十多年来首个获得美国FDA批准用于治疗痤疮的类维生素A分子。

高德美(Galderma)公司宣布,美国食品药品监督管理局(FDA)批准了0.005%AKLIEF(trifarotene)乳膏,用于痤疮的局部治疗。AKLIEF乳霜是唯一选择性靶向视黄酸受体(RAR)γ(皮肤中最常见的RAR)的局部类维生素A。Trifarotene是二十多年来首个获得美国FDA批准用于治疗痤疮的类维生素A分子。AKLIEF面霜是第一个经过专门研究并证明可治疗面部(前额,脸颊,鼻子和下巴)和截头(胸部,肩膀和背部)痤疮的局部治疗药物,为痤疮患者提供了另一种治疗选择。


"虽然类视色素是治疗痤疮的基础疗法,但数十年来几乎没有创新," AKLIEF Cream临床试验研究人员,阿肯色州史密斯堡Fort Johnson皮肤病学家,皮肤病学专家Sandra Johnson表示。"AKLIEF乳膏的获批,我很高兴为患者提供一种独特的,高度针对性的类维生素A,可减轻面部,背部,胸部和肩膀的炎症性病变,而且这种安全性和耐受性也得到证明。"


原始出处:


http://www.firstwordpharma.com/node/1671885?tsid=4#axzz61Nk0WbeB


本文系梅斯医学(MedSci)原创编译整m理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri May 08 13:03:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405933, encodeId=7cbb14059337a, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420033, encodeId=4c92142003387, content=<a href='/topic/show?id=ae62e905291' target=_blank style='color:#2F92EE;'>#维生素A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79052, encryptionId=ae62e905291, topicName=维生素A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e3553736, createdName=wwzzly, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425826, encodeId=23151425826bb, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469413, encodeId=20a2146941303, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-05-08 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri May 08 13:03:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405933, encodeId=7cbb14059337a, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420033, encodeId=4c92142003387, content=<a href='/topic/show?id=ae62e905291' target=_blank style='color:#2F92EE;'>#维生素A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79052, encryptionId=ae62e905291, topicName=维生素A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e3553736, createdName=wwzzly, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425826, encodeId=23151425826bb, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469413, encodeId=20a2146941303, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 chg122
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri May 08 13:03:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405933, encodeId=7cbb14059337a, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420033, encodeId=4c92142003387, content=<a href='/topic/show?id=ae62e905291' target=_blank style='color:#2F92EE;'>#维生素A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79052, encryptionId=ae62e905291, topicName=维生素A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e3553736, createdName=wwzzly, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425826, encodeId=23151425826bb, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469413, encodeId=20a2146941303, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 wwzzly
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri May 08 13:03:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405933, encodeId=7cbb14059337a, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420033, encodeId=4c92142003387, content=<a href='/topic/show?id=ae62e905291' target=_blank style='color:#2F92EE;'>#维生素A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79052, encryptionId=ae62e905291, topicName=维生素A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e3553736, createdName=wwzzly, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425826, encodeId=23151425826bb, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469413, encodeId=20a2146941303, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri May 08 13:03:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405933, encodeId=7cbb14059337a, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420033, encodeId=4c92142003387, content=<a href='/topic/show?id=ae62e905291' target=_blank style='color:#2F92EE;'>#维生素A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79052, encryptionId=ae62e905291, topicName=维生素A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e3553736, createdName=wwzzly, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425826, encodeId=23151425826bb, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469413, encodeId=20a2146941303, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 zhangjingnwpu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1839726, encodeId=4b4d1839e26f3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Fri May 08 13:03:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405933, encodeId=7cbb14059337a, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420033, encodeId=4c92142003387, content=<a href='/topic/show?id=ae62e905291' target=_blank style='color:#2F92EE;'>#维生素A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79052, encryptionId=ae62e905291, topicName=维生素A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c60e3553736, createdName=wwzzly, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425826, encodeId=23151425826bb, content=<a href='/topic/show?id=a1e44e62210' target=_blank style='color:#2F92EE;'>#局部治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47622, encryptionId=a1e44e62210, topicName=局部治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469413, encodeId=20a2146941303, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587548, encodeId=1748158e548f7, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Oct 07 02:03:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2019-10-07 xuqianhua